DrugPatentWatch Database Preview
Drugs in Development Information for Pf-04531083
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Pf-04531083?
Pf-04531083 is an investigational drug.
There have been 6 clinical trials for Pf-04531083.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2011.
The most common disease conditions in clinical trials are Chronic Pain, Toothache, and [disabled in preview]. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are twenty-four US patents protecting this investigational drug and two hundred and ninety international patents.
Summary for Pf-04531083
| US Patents | 24 |
| International Patents | 290 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 29 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2011-10-01) |
| Vendors | 8 |
Recent Clinical Trials for Pf-04531083
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain | Pfizer | Phase 2 |
| Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin | Pfizer | Phase 1 |
| A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers. | Pfizer | Phase 1 |
Clinical Trial Summary for Pf-04531083
Top disease conditions for Pf-04531083
Top clinical trial sponsors for Pf-04531083
US Patents for Pf-04531083
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Pf-04531083 | Start Trial | Substituted pyridazines for the treatment of pain | INHIBITAXIN LIMITED (Sandwich Kent, GB) | Start Trial |
| Pf-04531083 | Start Trial | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (Boston, MA) | Start Trial |
| Pf-04531083 | Start Trial | Pyridine derivatives | Pfizer Inc. (New York, NY) | Start Trial |
| Pf-04531083 | Start Trial | Sulfonamide derivatives | Pfizer Limited (Sandwich, GB) Icagen, Inc. (Durham, NC) | Start Trial |
| Pf-04531083 | Start Trial | Sulfonamide derivatives | Pfizer Limited (Sandwich, GB) Icagen, Inc. (Durham, NC) | Start Trial |
| Pf-04531083 | Start Trial | Sulfonamide derivatives as Nav 1.7 inhibitors | Pfizer Limited (Sandwich, GB) | Start Trial |
| Pf-04531083 | Start Trial | Peptide analogues | Pfizer Inc. (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Pf-04531083
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Pf-04531083 | Canada | 2853231 | 2031-10-28 | Start Trial |
| Pf-04531083 | China | 103958481 | 2031-10-28 | Start Trial |
| Pf-04531083 | China | 106220572 | 2031-10-28 | Start Trial |
| Pf-04531083 | European Patent Office | 2771325 | 2031-10-28 | Start Trial |
| Pf-04531083 | European Patent Office | 3243815 | 2031-10-28 | Start Trial |
| Pf-04531083 | Spain | 2648901 | 2031-10-28 | Start Trial |
| Pf-04531083 | Hong Kong | 1200455 | 2031-10-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
